On June 20, 2019, at the 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of OPKO Health, Inc., (the “Company”), the Company\’s stockholders approved an amendment to the Company\’s amended and restated certificate of incorporation (the “Certificate of Incorporation”) to increase the number of authorized shares of the common stock that may be issued from 750 million shares to 1 billion shares (the “Charter Amendment”), as described in the Company\’s 2019 Proxy Statement (the “2019 Proxy Statement”) on Schedule 14A filed with the Securities and Exchange Commission on April 26, 2019. The Charter Amendment was filed with the Secretary of State of the State of Delaware on June 20, 2019 and became effective on such date. The Charter Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K and incorporated by reference in this Item 5.03.

On June 20, 2019, the Company held the Annual Meeting. Below is a summary of the proposals and corresponding votes.

No other matters were considered or voted upon at the meeting.

A message from Dr. Phillip Frost, Chairman and Chief Executive Officer, has been posted to the Company’s website at www.opko.com. As previously disclosed in the 2019 Proxy Statement, questions pertinent to meeting matters that could not be answered during the Annual Meeting due to time constraints will be posted online. Such answers have been incorporated in or addressed in the remarks from Dr. Frost.

Exhibit List

Opko Health, Inc. Exhibit
EX-3.1 2 amendedrestatedcertofinc6-.htm EXHIBIT 3.1 Exhibit Exhibit 3.1CERTIFICATE OF AMENDMENTTOAMENDED AND RESTATED CERTIFICATE OF INCORPORATIONOFOPKO HEALTH,…
To view the full exhibit click here

About OPKO Health, Inc. (NASDAQ:OPK)

OPKO Health, Inc. (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations. The Company’s diagnostics business includes Bio-Reference Laboratories (Bio-Reference), which is a clinical laboratory with a genetic testing business, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Its pharmaceutical business includes OPKO Biologics, which features hGH-CTP, a once-weekly human growth hormone injection (in Phase III and partnered with Pfizer), and a longer acting Factor VIIa drug for hemophilia (Phase IIa). In addition to its pharmaceutical and diagnostic development programs, it owns pharmaceutical platforms in Ireland, Chile, Spain and Mexico.